^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LM-101

    i
    Other names: LM-101, LM 101, LM101
    Associations

    News

    Trials
    Company:
    LaNova Medicines Limited
    Drug class:
    SIRPA antagonist
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=145, Suspended, LaNova Medicines Limited
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101
    1year
    A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=145, Suspended, LaNova Medicines Limited | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101
    almost2years
    A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=145, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101
    2years
    A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=145, Not yet recruiting, LaNova Medicines Limited
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101